IP Library Granted Patent US 12,215,149
Granted Patent B2
US 12,215,149 · App. 17/722,624 · Granted Feb 4, 2025

Anti-MS4A6A antibodies and methods of use thereof

Inventors: Philip Kong (San Francisco, CA); Herve Rhinn (San Francisco, CA); Tina Schwabe (San Francisco, CA); Angie Yee (San Francisco, CA); Arnon Rosenthal (Woodside, CA)
Assignee: Alector LLC
C07K16/28A61P25/28A61K2039/505C07K2317/565C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,215,149
App. No.
17/722,624
Granted
Feb 4, 2025
Kind
B2
Abstract

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A6A polypeptide, e g., a mammalian MS4A6A or human MS4A6A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Claims (49)

1. An isolated antibody that binds to human MS4A6A, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein:

(i) the heavy chain variable region comprises

an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 14;

an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 29;

an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 43; and

the light chain variable region comprises:

an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 57;

an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 73; and

an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 84;

or

(ii) the heavy chain variable region comprises:

an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 11;

an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 24;

an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; and

the light chain variable region comprises:

an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 53;

an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 68; and

an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 84.

2. The antibody of claim 1 , wherein the antibody comprises

an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 14;

an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 29;

an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 43;

an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 57;

an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 73; and

an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 84.

3. The antibody of claim 2 , wherein the heavy chain variable region and light chain variable region comprise the amino acid sequences of SEQ ID NOs: 104 and 121, respectively.

4. The antibody of claim 2 , wherein the antibody is a monoclonal antibody.

5. The antibody of claim 3 , wherein the antibody is of the IgG class, the IgM class, or the IgA class.

6. The antibody of claim 5 , wherein the antibody is of the IgG class and has an IgG1, IgG2, or IgG4 isotype.

7. The antibody of claim 3 , wherein the antibody is an antibody fragment.

8. The antibody of claim 7 , wherein the fragment is a Fab, Fab′, Fab′-SH, F(ab′)2, Fv or scFv fragment.

9. The antibody of claim 2 , wherein the antibody is a multispecific antibody comprising a first antigen binding region that binds to MS4A6A and a second antigen binding region that binds to a second target, wherein the second target is

a protein, lipid, polysaccharide, or glycolipid expressed on one or more tumor cells.

10. A pharmaceutical composition comprising the antibody of claim 2 and a pharmaceutically acceptable carrier.

11. A pharmaceutical composition comprising the antibody of claim 3 and a pharmaceutically acceptable carrier.

12. The antibody of claim 1 , wherein the antibody comprises

an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 11;

an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 24;

an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39;

an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 53;

an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 68; and

an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 84.

13. The antibody of claim 12 , wherein the heavy chain variable region and light chain variable region comprises the amino acid sequences of SEQ ID NOs: 98 and 116, respectively.

14. The antibody of claim 13 , wherein the antibody is of the IgG class, the IgM class, or the IgA class.

15. The antibody of claim 14 , wherein the antibody is of the IgG class and has an IgG1, IgG2, or IgG4 isotype.

16. The antibody of claim 13 , wherein the antibody is an antibody fragment.

17. The antibody of claim 16 , wherein the fragment is a Fab, Fab′, Fab′-SH, F (ab′) 2, Fv or scFv fragment.

18. A pharmaceutical composition comprising the antibody of claim 12 and a pharmaceutically acceptable carrier.

19. A pharmaceutical composition comprising the antibody of claim 14 and a pharmaceutically acceptable carrier.

Assignments (4)
SECURITY INTEREST Recorded Nov 14, 2024
From: ALECTOR, INC.; ALECTOR LLC
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 069386/0141 →
CHANGE OF ADDRESS Recorded Oct 23, 2024
From: ALECTOR LLC
To: ALECTOR LLC
Reel/Frame 069228/0342 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2024
From: KONG, PHILIP; RHINN, HERVE; SCHWABE, TINA; YEE, ANGIE; ROSENTHAL, ARNON
To: ALECTOR LLC
Reel/Frame 068969/0915 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2024
From: KONG, PHILIP; RHINN, HERVE; SCHWABE, TINA; YEE, ANGIE; ROSENTHAL, ARNON
To: ALECTOR LLC
Reel/Frame 068970/0011 →
Continuity (4)
Continuation 16965675
Provisional Application 62624578 · Jan 31, 2018
Provisional Application 62646846 · Mar 22, 2018
Related Publication 20220380455A1 · Dec 1, 2022
References Cited (110)
US 9969799B2 · Wang et al. · 2018 [cited by applicant]
US 11472874B2 · Kong et al. · 2022 [cited by applicant]
US 11667699B2 · Sun et al. · 2023 [cited by applicant]
US 20090011409A1 · Sharma et al. · 2009 [cited by applicant]
US 20110027297A1 · Sahin et al. · 2011 [cited by applicant]
US 20160376359A1 · Wang et al. · 2016 [cited by applicant]
US 20170355756A1 · Julien et al. · 2017 [cited by applicant]
US 20210040200A1 · Kong et al. · 2021 [cited by applicant]
US 20210079074A1 · Sun et al. · 2021 [cited by applicant]
US 20210122817A1 · Kong et al. · 2021 [cited by applicant]
US 20230126400A1 · Kong et al. · 2023 [cited by applicant]
US 20240076362A1 · Sun et al. · 2024 [cited by applicant]
CN 101001879A · 2007 [cited by applicant]
CN 101998992A · 2011 [cited by applicant]
CN 105759057A · 2016 [cited by applicant]
CN 105969901A · 2016 [cited by applicant]
WO WO2002062946A2 · 2002 [cited by applicant]
WO WO2003035689A1 · 2003 [cited by applicant]
WO WO2005040796A1 · 2005 [cited by applicant]
WO WO2005123779A2 · 2005 [cited by applicant]
WO WO2008068048A2 · 2008 [cited by applicant]
WO WO2011147851A1 · 2011 [cited by applicant]
WO WO2017143036A1 · 2017 [cited by applicant]
WO WO2019152706A1 · 2019 [cited by applicant]
WO WO2019152715A1 · 2019 [cited by applicant]
WO WO2020160468A1 · 2020 [cited by applicant]
WO WO2021022083A2 · 2021 [cited by applicant]
WO WO2021081101A1 · 2021 [cited by applicant]
WO WO2024086796A1 · 2024 [cited by applicant]
Edwards et al., The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS. J Mol Biol. Nov. 14, 2003;334(1):103-18. (Year: 2003). [cited by examiner]
Allen, M., et al., “Novel late-onset Alzheimer disease loci variants associate with brain gene expression,” [cited by applicant]
Antúnez, C., et al., “The membrane-spanning 4-domains, subfamily A (MS4A) gene cluster contains a common variant associated with Alzheimer's disease,” [cited by applicant]
Arnett, M.J., et al., “Pro-NGF, Sortilin, and p75 [cited by applicant]
Barber, R.C., “The Genetics of Alzheimer's Disease,” [cited by applicant]
Beattie, M.S., et al., “ProNGF Induces p75-mediated Death of Oligodendrocytes Following Spinal Cord Injury,” [cited by applicant]
Bubien, J.K., et al., “Transfection of the CD20 Cell Surface Molecule Into Ectopic Cell Types Generates a Ca2+ Conductance Found Constitutively in B Lymphocytes,” [cited by applicant]
Cruse, G., et al., “The CD20 Homologue MS4A4 Directs Trafficking of KIT Toward Clathrin-independent Endocytosis Pathways and Thus Regulates Receptor Signaling and Recycling,” [cited by applicant]
Efthymiou, A.G., and Goate A.M., “Late Onset Alzheimer's Disease Genetics Implicates Microglial Pathways in Disease Risk,” [cited by applicant]
Elias-Sonnenschein, L.S., et al., “Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort,” [cited by applicant]
Fahnestock, M., et al., “The Precursor Pro-nerve Growth Factor is the Predominant Form of Nerve Growth Factor in Brain and is Increased in Alzheimer's Disease,” [cited by applicant]
Fan, Y.J., et al., “Differential Effects of Pro-BDNF on Sensory Neurons After Sciatic Nerve Transection in Neonatal Rats,” [cited by applicant]
Greer, P.L., et al., “A Family of Non-GPCR Chemosensors Defines an Alternative Logic for Mammalian Olfaction,” [cited by applicant]
Harrington, A.W., et al., “Secreted ProNGF is a Pathophysiological Deat-inducing Ligand After Adult CNS Injury,” [cited by applicant]
Hollingworth, P., et al., “Common Variants at ABCA7, MS4A6AIMS4A4E, EPHA1, CD33 and CD2AP Are Associated With Alzheimer's Disease,” [cited by applicant]
Hu, X., et al., “Genome-wide association study identifies multiple novel loci associated with disease progression in subjects with mild cognitive impairment,” [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/016141, Korean Intellectual Property Office, Korea, mailed on May 30, 2019, 11 pages. [cited by applicant]
Ishibashi, K., et al., “Identification of a New Multigene Four-transmembrane Family (MS4A) Related to CD20, HTm4 and β Subunit of the High-affinity IgE Receptor,” [cited by applicant]
Jansen, P., et al., “Roles for the Pro-neurotrophin Receptor Sortilin in Neuronal Development, Aging and Brain Injury,” [cited by applicant]
Karch, C.M., et al., “Expression of novel Alzheimer's disease risk genes in control and Alzheimer's disease brains,” [cited by applicant]
Karch, C.M., et al., “Alzheimer's disease risk genes and mechanisms of disease pathogenesis,” [cited by applicant]
Kay, B.K., et al., “The Importance of Being Proline: the Interaction of Proline-rich Motifs in Signaling Proteins With Their Cognate Domains,” [cited by applicant]
Koslowski, M., et al., “MS4A12 is a Colon-selective Store-operated Calcium Channel Promoting Malignant Cell Processes,” [cited by applicant]
Lacher, S.E., et al., “A Hypermorphic Antioxidant Response Element is Associated With Increased MS4A6A Expression and Alzheimer's Disease,” [cited by applicant]
Lambert, J.C., et al., “Meta-analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer's Disease,” [cited by applicant]
Liang, C.C., et al., “In Vitro Scratch Assay: a Convenient and Inexpensive Method for Analysis of Cell Migration in Vitro,” [cited by applicant]
Liang, Y., and Tedder, T.F., “Identification of a CD20-, FcεRIβ-, and HTm4-related Gene Family: Sixteen New MS4A Family Members Expressed in Human and Mouse,” [cited by applicant]
Ma, J., et al., “MS4A Cluster in Alzheimer's Disease,” [cited by applicant]
Ma, J., et al., “MS4A6A genotypes are associated with the atrophy rates of Alzheimer's disease related brain structures,” [cited by applicant]
Maximov, A., et al., “Monitoring Synaptic Transmission In Primary Neuronal Cultures Using Local Extracellular Stimulation,” [cited by applicant]
Naj, A.C., et al., “Common Variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHAI Are Associated With Late-onset Alzheimer's Disease,” [cited by applicant]
Nakamura, K., et al., “Intracellular Sortilin Expression Pattern Regulates ProNGF-induced Naturally Occurring Cell Death During Development,” [cited by applicant]
Nykjaer, A., et al., “Sortilin is Essential for ProNGF-induced Neuronal Cell Death,” [cited by applicant]
Nykjaer, A., et al., “p75 [cited by applicant]
Proitsi, P., et al. “Alzheimer's disease susceptibility variants in the MS4A6A gene are associated with altered levels of MS4A6A expression in blood,” [cited by applicant]
Provenzano, M.J., et al., “p75 [cited by applicant]
Shawi, R.A., et al., “Neurotoxic and Neurotrophic Roles of ProNGF and the Receptor Sortilin in the Adult and Ageing Nervous System,” [cited by applicant]
Teng, H.K., et al., “ProBDNF Induces Neuronal Apoptosis via Activation of a Receptor Complex of p75 [cited by applicant]
Volosin, M., et al., “Induction of Proneurotrophins and Activation of p75 [cited by applicant]
Volosin, M., et al., “Interaction of Survival and Death Signaling in Basal Forebrain Neurons: Roles of Neurotrophins and Proneurotrophins,” [cited by applicant]
Wei, Y., et al., “Enhanced Protein Expressions of Sortilin and p75 [cited by applicant]
Yano, H., et al., “Proneurotrophin-3 Is a Neuronal Apoptotic Ligand:Evidence for Retrograde-Directed Cell Killing,” [cited by applicant]
Chen, C., et al., “Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations,” EMBO Journal 14(12):2784-2794, Oxford University Press, Un… [cited by applicant]
Deming, Y., et al., “The MS4A gene cluster is a key regulator of soluble TREM2 and Alzheimer disease risk,” [cited by applicant]
Denardo, D.G., et al., “Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy,” [cited by applicant]
Dondelinger, M., et al., “Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition,” Front Immunol 9:2278, Frontiers Media SA., Switzerland (Oct. 2018). [cited by applicant]
Drake, A.W., and Klakamp, S.L., “A Rigorous Multiple Independent Binding Site Model for Determining Cell-based Equilibrium Dissociation Constants,” [cited by applicant]
Engle, S.J., et al., “Best Practices For Translational Disease Modeling Using Human iPSC-derived Neurons,” [cited by applicant]
He Li, W., “Research progress in MS4A gene family and tumor,” Tumor 36:345-350, China Academic Journal Electronic Publishing House, China (Mar. 2016). [cited by applicant]
He Li, W., “Research progress on MS4A gene family and clinically relevant diseases,” Chin J Clin Lab Sci 34(3):202-204, Chinese Medical Journals Publishing House, China (Mar. 2016). [cited by applicant]
Idusogie, E.E., et al., “Mapping of the Clq Binding Site on Rituxan, A Chimeric Antibody with a Human IgG1 Fc,” [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2019/016156, European Patent Office, Netherlands, mailed on Apr. 23, 2019, 13 pages. [cited by applicant]
International Search Report and Written Opinion mailed Jan. 28, 2021, in Application No. PCT/US2020/044335, EPO, Netherlands, 15 pages. [cited by applicant]
International Search Report for International Application No. PCT/US2019/016141, Korean Intellectual Property Office, Republic of Korea, mailed May 20, 2019, 11 pages. [cited by applicant]
Koenig, P., et al., “Mutational landscape of antibody variable domains reveals a switch modulating the interdomain conformational dynamics and antigen binding,” [cited by applicant]
Kuek, L.E., et al., “The MS4A family: counting past 1, 2 and 3,” [cited by applicant]
Kussie, P.H., et al., “A Single Engineered Amino Acid Substitution Changes Antibody Fine Specificity,” Journal of Immunology 152(1):146-152, American Association of Immunology, United States (1994). [cited by applicant]
Morris, G.E., “Epitope Mapping of Protein Antigens by Competition ELISA,” The Protein Protocols Handbook, pp. 595-600, Humana Press, United States (1996). [cited by applicant]
Murthy, M.N., et al., “Increased Brain Expression of GPNMB Is Associated with Genome Wide Significant Risk for Parkinson's Disease on Chromosome 7p15.3,” [cited by applicant]
Office Action mailed Feb. 28, 2022, in U.S. Appl. No. 16/965,676, Kong, P., et al., filed Jul. 29, 2020, 16 pages. [cited by applicant]
Office Action mailed Jun. 16, 2022, in U.S. Appl. No. 16/943,123, Sun, J., et al., filed Jul. 30, 2020, 7 pages. [cited by applicant]
Office Action mailed Oct. 18, 2021 in U.S. Appl. No. 16/943,123, Sun, J., et al., filed Jul. 30, 2020, 15 pages. [cited by applicant]
Office Action mailed Oct. 3, 2022, in U.S. Appl. No. 16/943,123, Sun, J., et al., filed Jul. 30, 2020, 3 pages. [cited by applicant]
Peng, X., et al., “Preclinical Evaluation of 3D185, a Novel Potent Inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-Dependent and Macrophage-Dominant Cancer models,” [cited by applicant]
Piccio, L., et al., “Cerebrospinal Fluid Soluble TREM2 is Higher in Alzheimer Disease and Associated With Mutation Status,” [cited by applicant]
Pocock, J.M., et al., “Modelling Microglial Function With Induced Pluripotent Stem Cells: An Update,” [cited by applicant]
Puri, M., et al., “The Evaluation of MS4A4A and MS4A8B Expression in Hematopoietic Cells,” retrieved from: https://prism.ucalgary.ca/bitstream/handle/11023/1791/ucalgary2014purmandip.pdf;jsessionid=cda23b615634fb7f5836e… [cited by applicant]
Reitz, C., “Toward Precision medicine in Alzheimer's Disease,” Ann. Transl. Med 4(6):107, 7 pages, AME Publishing Corp, United States (2016). [cited by applicant]
Rudikoff, S., et al., “Single amino acid substitution altering antigen-binding specificity,” Proc Natl Acad Sci USA 79(6):1979-1983, National Academy of Sciences, United States (Mar. 1982). [cited by applicant]
Salimi, A., et al., “Comparison Of Different Protocols For Neural Differentiation Of Human Induced Pluripotent Stem Cells,” [cited by applicant]
Sanyal, R., et al., “MS4A4A: a novel cell surface marker for M2 macrophages and plasma cells,” [cited by applicant]
Sekine, S. “The Current State and the Issues of Antibody Drugs,” [cited by applicant]
Sela-Culang, I., et al., “The structural basis of antibody-antigen recognition,” Front Immunol 4:302, Frontiers Media SA., Switzerland (Oct. 2013). [cited by applicant]
Shang, L., et al., “Selective Antibody Intervention of Toll-like Receptor 4 Activation through Fc γ Receptor Tethering,” [cited by applicant]
Shih-Feng, Y., et al., “MS4A4A modifies the risk of Alzheimer disease by regulating lipid metabolism and immune response in a unique microglia state,” MedRxiv 10.1101/2023.02.06.23285545, accessed at https://www.medrixi… [cited by applicant]
Stanford Health Now, “Alzheimer's Prevention, Treatment and Research—A Q&A with Dr. Frank Longo,” retrieved from: stanfordhealthcare.org/Stanford-health-now/2016/alzheimers-prevention-treatment-research-qa-longo.html, a… [cited by applicant]
TCW, J., et al., “An Efficient Platform For Astrocyte Differentiation From Human Induced Pluripotent Stem Cells,” [cited by applicant]
Thornton, P., et al., “TREM2 shedding by cleavage at the H157-S158 bond is accelerated for the Alzheimer's disease-associated H157Y variant,” [cited by applicant]
Tomay, F., “Regulation and function of the tetraspanin-like molecule MS4A4A in alternatively activated and tumor-associated macrophages,” XP055578452, Retrieved from the Internet: https://air.unimi.it/retrieve/handle/24… [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2023/077418, European Patent Office, Netherlands, mailed Feb. 12, 2024, 11 pages. [cited by applicant]
NCBI, “Membrane-spanning 4-domains subfamily A member 4A isoform 1 [ [cited by applicant]